DURECT (DRRX -31.8%) slumps on more than double normal volume in early trade in reaction to unsuccessful results from a Phase 2a clinical trial evaluating a topical formulation of DUR-928 in 22 patients with mild-to-moderate plaque psoriasis.
DUR-928 failed to demonstrate a treatment effect compared to placebo as measured by a scale called IGA (primary endpoint). All secondary endpoints were missed as well.
On a positive note, DUR-928 was safe and well-tolerated.
The company has terminated development for the indication.
Development is ongoing for oral formulations in alcoholic hepatitis and primary sclerosing cholangitis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.